Stifel Financial’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-10,026
| Closed | -$394K | – | 3454 |
|
|
2023
Q2 | $394K | Sell |
10,026
-1,949
| -16% | -$68.8K | ﹤0.01% | 2668 |
|
|
2023
Q1 | $291K | Buy |
+11,975
| New | +$262K | ﹤0.01% | 2834 |
|
|
2016
Q4 | – | Sell |
-13,045
| Closed | -$607K | – | 2571 |
|
|
2016
Q3 | $607K | Sell |
13,045
-4,861
| -27% | -$274K | ﹤0.01% | 1618 |
|
|
2016
Q2 | $915K | Buy |
17,906
+2,058
| +13% | +$102K | ﹤0.01% | 1392 |
|
|
2016
Q1 | $670K | Sell |
15,848
-830
| -5% | -$42.3K | ﹤0.01% | 1429 |
|
|
2015
Q4 | $1.31M | Buy |
16,678
+8,412
| +102% | +$486K | 0.01% | 1169 |
|
|
2015
Q3 | $335K | Sell |
8,266
-56,136
| -87% | -$2.97M | ﹤0.01% | 1776 |
|
|
2015
Q2 | $3.35M | Sell |
64,402
-115,907
| -64% | -$5.77M | 0.02% | 743 |
|
|
2015
Q1 | $8.39M | Sell |
180,309
-3,519
| -2% | -$183K | 0.05% | 457 |
|
|
2014
Q4 | $12.8M | Buy |
+183,828
| New | +$7.72M | 0.07% | 332 |
|
|
2014
Q2 | – | Sell |
-10,922
| Closed | -$390K | – | 2273 |
|
|
2014
Q1 | $390K | Buy |
+10,922
| New | +$368K | ﹤0.01% | 1564 |
|
Stifel Financial's ISEE Position: Q3 2023 in Review
Stifel Financial sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q3 2023, closing a stake of 10,026 shares — an estimated $394K sold.
Stifel Financial first reported a position in ISEE in Q1 2014 and held it in 11 quarters. The position peaked at $12.8M in Q4 2014. 0 funds tracked by Wall St. Rank hold ISEE as of Q3 2023.
- Stifel Financial reported no remaining IVERIC bio, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Stifel Financial sold 10,026 IVERIC bio, Inc. Common Stock shares in Q3 2023, an estimated $394K.
- Stifel Financial first reported a position in IVERIC bio, Inc. Common Stock in Q1 2014 and held it in 11 quarters.
- Stifel Financial's IVERIC bio, Inc. Common Stock position peaked at $12.8M in Q4 2014.
- 0 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q3 2023.
Based on Stifel Financial's 13F filing for Q3 2023, filed 13 Nov 2023.